Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has exhibited strong revenue growth, with Q3'25 revenues reaching $27.3 million, reflecting a 63.3% year-over-year increase, significantly surpassing estimates. Management has revised upward its revenue projections for 2025 and 2026 to $97.5 million and $136 million, respectively, indicating confidence in sustained growth driven by robust new patient starts, particularly from the pharmacy channel. The company’s expansion into multiple daily injection patient conversions and the addition of sales territories further positions it for continued market penetration and higher-margin sales in the upcoming years.

Bears say

Beta Bionics Inc faces significant risks that could adversely impact its financial outlook, including challenges in gaining market share for its iLet product amidst competitive pressures and potential hurdles in expanding pharmacy channel access. The company's projected EBITDA loss of $12.2 million significantly exceeded earlier estimates, indicating financial strain and raising concerns about profitability. Additionally, the need for further capital may lead to shareholder dilution, compounded by uncertainties in Medicare reimbursement models and a slower-than-anticipated sales force ramp-up, which could hinder revenue growth moving forward.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.